2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Benefits in Previously Treated, CLDN18.2-positive Gastric Cancer...
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from...
Scage Future Announces Effective Date for ADS Ratio Change
NANJING, China, Oct. 23, 2026 /PRNewswire/ -- Scage Future ("Scage Future" or the "Company") (Nasdaq: SCAG), a provider of new energy and zero-emission heavy-duty commercial vehicles and e-fuel solutions, today announced the effective date and new...
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
TAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100,...
ESENTIA Announces Third Quarter 2026 Earnings Conference Call
MEXICO CITY, Oct. 22, 2026 /PRNewswire/ -- ESENTIA Energy Development, S.A.B de C.V. (BMV: ESENTIA) ("ESENTIA" or the "Company") will report its third quarter 2026 financial results after market close on Wednesday, October 28th, 2026. ESENTIA will...
WF Holding Limited Announces Termination of Additional Purchase Right
KUALA LUMPUR, Malaysia, Oct. 21, 2026 /PRNewswire/ -- WF Holding Limited (NASDAQ: WFF) (the "Company"), announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 14,...
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that...
China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right
TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on...
JinkoSolar Announces Results of 2026 Annual General Meeting
SHANGRAO, China, Oct. 21, 2026 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), today announced that all shareholders resolutions proposed at the Company's 2026 annual general meeting held today were duly...
Cohesity Announces FY2026 Partner Award Winners
Recognition highlights top performers across Cohesity's partner ecosystem, including alliances, distributors, resellers, global system integrators, and managed service providers SINGAPORE, Oct. 21, 2026 /PRNewswire/ -- Cohesity, the leader in AI and...